AndrewEPlaceMDPhD
Pediatric Hematology & Oncology • Boston, MAPediatric Hematologic Oncology
Co-Director, Hematologic Malignancy Program; Dana-Farber/Boston Children's Cancer and Blood Disorders Center Assistant Professor, Harvard Medical School
Dr. Place is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana 3-146
Boston, MA 02115Phone+1 617-632-2313
Summary
- Dr. Andrew Place is a pediatric hematologist/oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Boston Children's Hospital, Dana-Farber Cancer Institute, and Brigham and Women's Hospital. He received his medical degree from Geisel School of Medicine at Dartmouth and has been in practice 11 years. He specializes in pediatric hematologic oncology and is experienced in developmental therapeutics and relapsed/refractory leukemia.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2009 - 2012- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2006 - 2009
Geisel School of Medicine at DartmouthClass of 2006
Dartmouth CollegePhD, Pharmacology and Toxicology, 1998 - 2004
Certifications & Licensure
FL State Medical License 2022 - Present
NH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
CT State Medical License 2022 - 2025
MA State Medical License 2009 - 2025
ME State Medical License 2022 - 2025
VT State Medical License 2023 - 2024- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Start of enrollment: 2014 Mar 01
- Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL Start of enrollment: 2019 Jan 30
Publications & Presentations
PubMed
- 285 citationsThe microenvironment in breast cancer progression: biology and implications for treatmentAndrew E. Place, Sung Jin Huh, Kornelia Polyak
Breast Cancer Research. 2011-11-01 - 10 citationsEffect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.Shai Shimony, Yael Flamand, Yannis K Valtis, Andrew E Place, Lewis B Silverman
Blood Advances. 2023-09-26 - 85 citationsOutcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.Weili Sun, Jemily Malvar, Richard Sposto, Anupam Verma, Jennifer J. Wilkes
Leukemia. 2018-03-15
Abstracts/Posters
- Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...Andrew E. Place, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Pediatric Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a RowOctober 8th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
